newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

  • AEON Biopharma granted 392,158 restricted stock units to newly hired non-executive employees on December 11, 2025.
  • The awards were approved by the Board under the 2025 Inducement Incentive Plan in compliance with Section 711 of the NYSE American LLC Company Guide.
  • The RSUs vest over four years with 25% vesting annually on each anniversary of the December 2025 commencement date.
  • AEON is developing ABP-450 as a biosimilar to BOTOX to seek accelerated & full-label U.S. market entry for therapeutic neurotoxin indications.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry.
  • ABP-450 is the same botulinum toxin complex marketed by Evolus as Jeuveau for cosmetic indications.
  • ABP-450 is manufactured by Daewoong Pharmaceutical in a cGMP facility approved by the FDA, Health Canada, & the EMA.
  • The product is approved as a biosimilar in India, Mexico, & the Philippines.
  • AEON holds exclusive development & distribution rights for ABP-450 therapeutic indications in the U.S., Canada, the EU, the UK, & other international territories.
  • The FDA regulates biosimilars under the 351(k) pathway, requiring demonstration of high similarity to a reference biologic with no clinically meaningful differences.